1. Home
  2. VYNE vs ALLR Comparison

VYNE vs ALLR Comparison

Compare VYNE & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VYNE Therapeutics Inc.

VYNE

VYNE Therapeutics Inc.

HOLD

Current Price

$0.68

Market Cap

22.3M

Sector

Health Care

ML Signal

HOLD

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.40

Market Cap

19.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYNE
ALLR
Founded
2003
2004
Country
United States
United States
Employees
10
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.3M
19.3M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
VYNE
ALLR
Price
$0.68
$1.40
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
N/A
$9.75
AVG Volume (30 Days)
232.7K
201.5K
Earning Date
05-08-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
33.33
N/A
EPS
N/A
N/A
Revenue
N/A
$320,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.77
52 Week High
$1.96
$2.35

Technical Indicators

Market Signals
Indicator
VYNE
ALLR
Relative Strength Index (RSI) 66.11 50.42
Support Level $0.56 $1.01
Resistance Level $0.69 $1.45
Average True Range (ATR) 0.02 0.13
MACD 0.00 -0.02
Stochastic Oscillator 88.82 31.25

Price Performance

Historical Comparison
VYNE
ALLR

About VYNE VYNE Therapeutics Inc.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.

Share on Social Networks: